Brinzolamide (BioDeep_00000006594)

 

Secondary id: BioDeep_00001867990

human metabolite blood metabolite


代谢物信息卡片


(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide

  化学式: C12H21N3O5S3 (383.0643)
中文名称: 布林佐胺
  谱图信息: 最多检出来源 Homo sapiens(blood) 6.62%

分子结构信息

SMILES: CCNC1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
InChI: InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1

描述信息

Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EC - Carbonic anhydrase inhibitors
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
D004791 - Enzyme Inhibitors > D002257 - Carbonic Anhydrase Inhibitors
C471 - Enzyme Inhibitor > C29577 - Carbonic Anhydrase Inhibitor

同义名列表

69 个代谢物同义名

(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1λ⁶-thieno[3,2-e][1,2]thiazine-6-sulfonamide; Allphar brand OF brinzolamide; Alcon brand OF brinzolamide; Brinzolamide; CHEMBL6750; Azopt; Tox21_110722_1; Brinzolamide; (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1lambda6-thieno[3,2-e][1,2]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno(3,2-e)(1,2)thiazine-6-sulfonamide 1,1-dioxide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide; (4R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (4R)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide; (5R)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide; (5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2?6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide; (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; (R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2,e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; 2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4R)-; 3znc; AZARGA COMPONENT BRINZOLAMIDE; Azopt (TN); BPBio1_000539; Brinzolamida; Brinzolamide - Bio-X trade mark; Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); BRINZOLAMIDE (MART.); Brinzolamide (Standard); BRINZOLAMIDE (USP IMPURITY); BRINZOLAMIDE (USP MONOGRAPH); BRINZOLAMIDE (USP-RS); BRINZOLAMIDE [EMA EPAR]; BRINZOLAMIDE [INN]; BRINZOLAMIDE [JAN]; BRINZOLAMIDE [MART.]; BRINZOLAMIDE [MI]; BRINZOLAMIDE [ORANGE BOOK]; Brinzolamide [USAN:USP:INN:BAN]; Brinzolamide [USAN]; BRINZOLAMIDE [USP IMPURITY]; BRINZOLAMIDE [USP MONOGRAPH]; BRINZOLAMIDE [USP-RS]; BRINZOLAMIDE [VANDF]; BRINZOLAMIDE [WHO-DD]; BRINZOLAMIDE COMPONENT OF AZARGA; BRINZOLAMIDE COMPONENT OF SIMBRINZA; Brinzolamide, >=98% (HPLC); Brinzolamide, United States Pharmacopeia (USP) Reference Standard; brinzolamidum; BZ1; HCRKCZRJWPKOAR-JTQLQIEISA-N; Prestwick0_000365; Prestwick1_000365; Prestwick2_000365; Prestwick3_000365; S01EC04; SIMBRINZA COMPONENT BRINZOLAMIDE; Tox21_110722



数据库引用编号

20 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome()

BioCyc()

PlantCyc()

代谢反应

个相关的代谢反应过程信息。

Reactome()

BioCyc()

WikiPathways()

Plant Reactome()

INOH()

PlantCyc()

COVID-19 Disease Map()

PathBank()

PharmGKB()

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 10 ADCY10, BCL2, BCL2L1, CA2, DCTN4, FLNA, GFAP, OAT, TPT1, VEGFA
Golgi apparatus, trans-Golgi network membrane 1 VPS13B
Peripheral membrane protein 3 ADCY10, RS1, VPS13B
Endoplasmic reticulum membrane 2 BCL2, IZUMO1
Mitochondrion membrane 1 BCL2L1
Nucleus 6 ADCY10, BCL2, DCTN4, FLNA, TPT1, VEGFA
autophagosome 1 MAP1LC3A
cytosol 10 ADCY10, AVP, BCL2, BCL2L1, CA2, DCTN4, FLNA, GFAP, MAP1LC3A, TPT1
dendrite 2 ADCY10, AVP
trans-Golgi network 2 CA4, FLNA
centrosome 2 BCL2L1, DCTN4
nucleoplasm 1 OAT
Cell membrane 8 ADCY10, ADRB3, CA2, CA4, IZUMO1, PTGER2, RS1, SLC4A4
Lipid-anchor 1 MAP1LC3A
Cytoplasmic side 2 ADCY10, BCL2L1
Cell projection, growth cone 1 FLNA
Early endosome membrane 1 VPS13B
Multi-pass membrane protein 4 ADRB3, PTGER2, SLC16A4, SLC4A4
cell cortex 1 DCTN4
cell surface 3 CA4, SLC4A4, VEGFA
dendritic shaft 1 FLNA
glutamatergic synapse 2 FLNA, MAP1LC3A
Golgi apparatus 2 CA4, VEGFA
Golgi membrane 1 VPS13B
lysosomal membrane 1 VPS13B
mitochondrial inner membrane 1 BCL2L1
neuronal cell body 1 ADCY10
postsynapse 1 FLNA
Cytoplasm, cytosol 1 BCL2L1
acrosomal vesicle 1 IZUMO1
plasma membrane 8 ADRB3, CA2, CA4, FLNA, IZUMO1, PTGER2, SLC16A4, SLC4A4
synaptic vesicle membrane 1 BCL2L1
Membrane 8 BCL2, CA4, FLNA, IZUMO1, PTGER2, SLC16A4, SLC4A4, VEGFA
apical plasma membrane 2 ADCY10, CA4
basolateral plasma membrane 1 SLC4A4
brush border 1 FLNA
extracellular exosome 5 CA2, CA4, FLNA, SLC4A4, TPT1
Lysosome membrane 1 VPS13B
endoplasmic reticulum 3 BCL2, BCL2L1, VEGFA
extracellular space 4 AVP, RS1, TPT1, VEGFA
perinuclear region of cytoplasm 3 ADCY10, CA4, FLNA
adherens junction 1 VEGFA
mitochondrion 4 ADCY10, BCL2, BCL2L1, OAT
protein-containing complex 2 BCL2, RS1
intracellular membrane-bounded organelle 1 MAP1LC3A
Single-pass type I membrane protein 1 IZUMO1
Secreted 3 AVP, RS1, VEGFA
extracellular region 4 ADCY10, AVP, FLNA, VEGFA
Mitochondrion outer membrane 2 BCL2, BCL2L1
Single-pass membrane protein 2 BCL2, BCL2L1
mitochondrial outer membrane 2 BCL2, BCL2L1
astrocyte end-foot 2 ADCY10, GFAP
basal part of cell 1 ADCY10
central region of growth cone 1 ADCY10
Mitochondrion matrix 2 BCL2L1, OAT
mitochondrial matrix 2 BCL2L1, OAT
Extracellular side 1 RS1
Cell projection, cilium 1 ADCY10
photoreceptor inner segment 1 RS1
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 2 BCL2L1, DCTN4
Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane 1 BCL2L1
Nucleus membrane 2 BCL2, BCL2L1
Bcl-2 family protein complex 2 BCL2, BCL2L1
nuclear membrane 2 BCL2, BCL2L1
external side of plasma membrane 2 CA4, RS1
Secreted, extracellular space, extracellular matrix 1 VEGFA
multivesicular body 1 TPT1
actin cytoskeleton 1 FLNA
perikaryon 1 FLNA
Z disc 1 FLNA
nucleolus 1 FLNA
apical part of cell 1 CA2
cell-cell junction 1 FLNA
Cytoplasm, perinuclear region 1 ADCY10
pore complex 1 BCL2
Cytoplasm, cytoskeleton 4 ADCY10, DCTN4, FLNA, MAP1LC3A
focal adhesion 2 DCTN4, FLNA
microtubule 1 MAP1LC3A
extracellular matrix 1 VEGFA
secretory granule 2 AVP, VEGFA
intermediate filament 1 GFAP
lateral plasma membrane 1 SLC4A4
Cytoplasm, myofibril, sarcomere 1 DCTN4
Late endosome 1 MAP1LC3A
sarcomere 1 DCTN4
neuron to neuron synapse 1 RS1
receptor complex 1 ADRB3
cilium 1 ADCY10
axonal growth cone 1 FLNA
Cytoplasmic vesicle, autophagosome membrane 1 MAP1LC3A
autophagosome membrane 1 MAP1LC3A
cell projection 1 GFAP
cytoskeleton 1 ADCY10
Cell projection, podosome 1 FLNA
podosome 1 FLNA
brush border membrane 1 CA4
spindle pole 2 DCTN4, TPT1
Cytoplasm, cell cortex 2 DCTN4, FLNA
actin filament 1 FLNA
Basolateral cell membrane 1 SLC4A4
Lipid-anchor, GPI-anchor 1 CA4
organelle membrane 1 MAP1LC3A
Recycling endosome membrane 1 VPS13B
Endomembrane system 1 MAP1LC3A
cell body 1 GFAP
side of membrane 1 CA4
myelin sheath 2 BCL2, CA2
intermediate filament cytoskeleton 1 GFAP
stress fiber 1 DCTN4
trans-Golgi network membrane 1 VPS13B
secretory granule membrane 1 CA4
platelet alpha granule lumen 1 VEGFA
dynactin complex 1 DCTN4
kinetochore 1 DCTN4
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 VPS13B
cytoplasmic dynein complex 1 DCTN4
neuronal dense core vesicle 1 AVP
Golgi apparatus, cis-Golgi network membrane 1 VPS13B
clathrin-coated endocytic vesicle membrane 1 AVP
Cytoplasm, cytoskeleton, stress fiber 1 DCTN4
endoplasmic reticulum-Golgi intermediate compartment 1 CA4
cytoplasmic microtubule 1 TPT1
apical dendrite 1 FLNA
intracellular non-membrane-bounded organelle 1 FLNA
Rough endoplasmic reticulum 1 CA4
cis-Golgi network membrane 1 VPS13B
acrosomal membrane 2 IZUMO1, VPS13B
Cytoplasmic vesicle, secretory vesicle, acrosome membrane 2 IZUMO1, VPS13B
cytoplasmic side of lysosomal membrane 1 GFAP
transport vesicle membrane 1 CA4
actin filament bundle 1 FLNA
cortical cytoskeleton 1 FLNA
Autolysosome 1 MAP1LC3A
glycoprotein Ib-IX-V complex 1 FLNA
Myb complex 1 FLNA
BAD-BCL-2 complex 1 BCL2
[N-VEGF]: Cytoplasm 1 VEGFA
[VEGFA]: Secreted 1 VEGFA
[Isoform L-VEGF189]: Endoplasmic reticulum 1 VEGFA
[Isoform VEGF121]: Secreted 1 VEGFA
[Isoform VEGF165]: Secreted 1 VEGFA
VEGF-A complex 1 VEGFA
protein complex involved in cell-cell adhesion 1 IZUMO1
[Isoform Bcl-X(L)]: Mitochondrion inner membrane 1 BCL2L1


文献列表

  • Liping Chen, Ruixin Wu. Brinzolamide- and latanoprost-loaded nano lipid carrier prevents synergistic retinal damage in glaucoma. Acta biochimica Polonica. 2022 May; 69(2):423-428. doi: 10.18388/abp.2020_5885. [PMID: 35617132]
  • Gen Suzuki, Eriko Kunikane, Wakasa Shigemi, Keisuke Shinno, Seiko Kozai, Masaaki Kurata, Akio Kawamura. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations. Current eye research. 2021 03; 46(3):380-386. doi: 10.1080/02713683.2020.1800046. [PMID: 32706598]
  • Vatsala Naageshwaran, Veli-Pekka Ranta, Glenwood Gum, Siddhartha Bhoopathy, Arto Urtti, Eva M Del Amo. Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration. Journal of pharmaceutical sciences. 2021 01; 110(1):529-535. doi: 10.1016/j.xphs.2020.09.051. [PMID: 33035542]
  • Nupur Shrivastava, Saba Khan, Sanjula Baboota, Javed Ali. Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery. Current drug delivery. 2018; 15(6):829-839. doi: 10.2174/1566523218666171129205626. [PMID: 29189155]
  • Alexandra Robciuc, Joanna Witos, Suvi-Katriina Ruokonen, Antti H Rantamäki, Pierre-Jean Pisella, Susanne K Wiedmer, Juha M Holopainen. Pure Glaucoma Drugs Are Toxic to Immortalized Human Corneal Epithelial Cells, but They Do Not Destabilize Lipid Membranes. Cornea. 2017 Oct; 36(10):1249-1255. doi: 10.1097/ico.0000000000001322. [PMID: 28825921]
  • Anargyros Foivas, Anđelija Malenović, Nađa Kostić, Marija Božić, Miroslav Knežević, Yannis L Loukas, Yannis Dotsikas. Quantitation of brinzolamide in dried blood spots by a novel LC-QTOF-MS/MS method. Journal of pharmaceutical and biomedical analysis. 2016 Feb; 119(?):84-90. doi: 10.1016/j.jpba.2015.11.043. [PMID: 26669612]
  • Billie Beckwith-Cohen, Ellison Bentley, David J Gasper, Gillian J McLellan, Richard R Dubielzig. Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma. Journal of the American Veterinary Medical Association. 2015 Dec; 247(12):1419-26. doi: 10.2460/javma.247.12.1419. [PMID: 26642138]
  • Imran Ali, Zeid A Al-Othman, Abdulrahman Al-Warthan, Syed Dilshad Alam, Javed A Farooqi. Enantiomeric separation and simulation studies of pheniramine, oxybutynin, cetirizine, and brinzolamide chiral drugs on amylose-based columns. Chirality. 2014 Mar; 26(3):136-43. doi: 10.1002/chir.22276. [PMID: 24464520]
  • Rajendra S Kadam, Gajanan Jadhav, Miller Ogidigben, Uday B Kompella. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug metabolism and disposition: the biological fate of chemicals. 2011 Sep; 39(9):1529-37. doi: 10.1124/dmd.111.040055. [PMID: 21673129]
  • Jorge A Alvarado, Rumiko Iguchi, Richard Juster, Julie A Chen, Amde Selassie Shifera. From the bedside to the bench and back again: predicting and improving the outcomes of SLT glaucoma therapy. Transactions of the American Ophthalmological Society. 2009 Dec; 107(?):167-81. doi: . [PMID: 20126493]
  • Mika Hilvo, Anna Maria Salzano, Alessio Innocenti, Markku S Kulomaa, Andrea Scozzafava, Andrea Scaloni, Seppo Parkkila, Claudiu T Supuran. Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. Journal of medicinal chemistry. 2009 Feb; 52(3):646-54. doi: 10.1021/jm801267c. [PMID: 19193158]
  • Benjamin Bakall, Precious McLaughlin, J Brett Stanton, Youwen Zhang, H Criss Hartzell, Lihua Y Marmorstein, Alan D Marmorstein. Bestrophin-2 is involved in the generation of intraocular pressure. Investigative ophthalmology & visual science. 2008 Apr; 49(4):1563-70. doi: 10.1167/iovs.07-1338. [PMID: 18385076]
  • Diana Melinte Dumitrica, C Stefan. [Open-angle glaucoma associated with Groenblad-Strandberg syndrome]. Oftalmologia (Bucharest, Romania : 1990). 2008; 52(4):44-52. doi: ". [PMID: 19354162]
  • M F Sugrue. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Progress in retinal and eye research. 2000 Jan; 19(1):87-112. doi: 10.1016/s1350-9462(99)00006-3. [PMID: 10614682]
  • A Scozzafava, F Briganti, G Mincione, L Menabuoni, F Mincione, C T Supuran. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. Journal of medicinal chemistry. 1999 Sep; 42(18):3690-700. doi: 10.1021/jm9901879. [PMID: 10479300]
  • A Scozzafava, L Menabuoni, F Mincione, F Briganti, G Mincione, C T Supuran. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?. Journal of medicinal chemistry. 1999 Jul; 42(14):2641-50. doi: 10.1021/jm9900523. [PMID: 10411484]
  • T Stams, Y Chen, P A Boriack-Sjodin, J D Hurt, J Liao, J A May, T Dean, P Laipis, D N Silverman, D W Christianson. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein science : a publication of the Protein Society. 1998 Mar; 7(3):556-63. doi: 10.1002/pro.5560070303. [PMID: 9541386]


Loading...